This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 18, 2013 /PRNewswire/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the sale of 6,100,000 shares of its common stock in an underwritten public offering at a price to the public of
$10.58 per share, the closing price of the stock on the previous day. The gross proceeds to Sangamo from the public offering are expected to be approximately
$65 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of common stock on the same terms and conditions, to cover over-allotments, if any. The offering is expected to close on or about
September 23, 2013, subject to customary closing conditions.
Sangamo anticipates using the net proceeds from this offering for general corporate purposes, including support for its continuing research and development of its ZFP Therapeutic product candidates and research programs, commercialization activities, clinical trials, business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to its business.
Lazard Capital Markets LLC, JMP Securities LLC and
Piper Jaffray & Co. are acting as joint book-running managers and Cowen and Company, LLC is acting as co-lead manager for the offering.
A shelf registration statement on Form S-3 relating to the public offering of shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on
April 12, 2012. A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at
www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor,
New York, NY 10020, or via telephone at 800-542-0970; or JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor,
San Francisco, CA 94111, or via telephone at 415-835-8985; or
Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, or via telephone at 800-747-3924.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.